Rocket Pharmaceuticals Inc (RCKT) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Rocket Pharmaceuticals Inc $1.09, price $3.02, upside -64.0%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rocket Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.33 – $48.97 · fair‑value band $0.7140 – $1.36 · the $3.02 price screens above the $1.09 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Rocket Pharmaceuticals in your weekly email
Every Wednesday you see whether Rocket Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Show more
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Stock analysis
Rocket Pharmaceuticals Inc (RCKT) currently trades at $3.02, while our model-based Fair Value estimate is $1.09, implying the stock looks roughly 177.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.7140 (bear) to $1.36 (bull), the price of $3.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Rocket Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$223M in FY2025.
Key figures
Market cap $378M · EPS (TTM) $−1.87 · Return on equity −64.4% · Return on assets (EBIT) −48.2% · Free cash flow −$190M · Net cash $52.7M.
What moves the price
The share trades about 45% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −64%, RCKT screens richer than that median.
Fair Value models
Bear $0.7140Fair Value $1.09Bull $1.36
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
News mood ⓘNews mood, the average tone of recent news (81 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Compare Rocket Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Below median
Fair Value upside−68% · Below median
Profitability
Return on assets−35% · Bottom 25%
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.34× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)94· sector 96
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rocket Pharmaceuticals Inc (RCKT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.09 versus a price of $3.02, about −64% upside (overvalued).
What is the fair value of RCKT?
Our model-based fair value for Rocket Pharmaceuticals Inc is $1.09 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.02.
What is the quality score of RCKT?
Rocket Pharmaceuticals Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rocket Pharmaceuticals Inc (RCKT)?
Our model-based price target is the fair value of $1.09 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.7140, optimistic scenario $1.36. It is a calculation from audited fundamentals, not an analyst target.
What is the Rocket Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $1.09, about −64% upside versus a price of $3.02 (overvalued). Cautious scenario $0.7140, optimistic scenario $1.36. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Rocket Pharmaceuticals Inc (RCKT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rocket Pharmaceuticals Inc it is $1.09 per share (as of Sep 24, 2026), against a price of $3.02. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Rocket Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RCKT trades above its calculated fair value: price $3.02, fair value $1.09, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RCKT?
No. The price is what the market pays today ($3.02); the fair value is what the company's own numbers justify ($1.09). For Rocket Pharmaceuticals Inc the two are $1.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rocket Pharmaceuticals Inc worth?
The market values Rocket Pharmaceuticals Inc at about $378M (market capitalisation, as of Sep 24, 2026). Per share that is $3.02; our models calculate a fair value of $1.09 per share.
What do the bullish and bearish scenarios say about RCKT?
Our models span a range for Rocket Pharmaceuticals Inc: cautious scenario $0.7140, base $1.09, optimistic $1.36 per share (as of Sep 24, 2026, price $3.02). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rocket Pharmaceuticals Inc (RCKT)?
Balance-sheet figures for Rocket Pharmaceuticals Inc (as of Sep 24, 2026): return on equity −64.4%, debt of 0.13 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is RCKT from its 52-week high?
Rocket Pharmaceuticals Inc trades at $3.02, about 45% below its 52-week high of $5.45 and 26% above the low of $2.40 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.09 is for.
Which stocks are comparable to Rocket Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rocket Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.02, calculated fair value $1.09 (−64%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RCKT calculated?
We run Rocket Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Rocket Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rocket Pharmaceuticals Inc (RCKT)?
The closing price on Sep 23, 2026 was $3.02. Our model-based fair value is $1.09, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rocket Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($1.36). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.7140 to $1.36) leaves room in how you read the outcome.
Key figures of Rocket Pharmaceuticals Inc
How large is the market capitalisation of Rocket Pharmaceuticals Inc (RCKT)?
The market capitalisation of Rocket Pharmaceuticals Inc is $378M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Rocket Pharmaceuticals Inc (RCKT)?
Earnings per share at Rocket Pharmaceuticals Inc are $−1.87. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rocket Pharmaceuticals Inc (RCKT)?
The return on equity (ROE) of Rocket Pharmaceuticals Inc is −64.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rocket Pharmaceuticals Inc (RCKT)?
On an EBIT basis the return on assets of Rocket Pharmaceuticals Inc is −48.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Rocket Pharmaceuticals Inc (RCKT) generate?
The free cash flow of Rocket Pharmaceuticals Inc is −$190M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rocket Pharmaceuticals Inc (RCKT) hold?
Rocket Pharmaceuticals Inc holds more cash than debt, $52.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rocket Pharmaceuticals Inc in the live analysis
One click puts Rocket Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026